• Has the ability to provide informed consent to participate in the study, in accordance with applicable regulations.

• Has an understanding, ability, and willingness to comply with study procedures and restrictions.

• ≥18 and \<65 years.

• Weight 50 to 110 kg, inclusive.

• Congenital Type 1 VWD, Type 1C and Type 2A VWD diagnosis as documented by laboratory results for VWF antigen and activity.

• Vital signs are within the following ranges at Screening:

∙ Resting pulse rate ≤105 bpm

‣ Blood pressure (BP):

⁃ Systolic blood pressure: 90 - 140 mmHg

• Diastolic blood pressure: 40 - 90 mmHg

• Participants assigned female at birth and of child-bearing potential must have a negative serum pregnancy test within 72 hours prior to the first dose of HMB-002.

• Women of childbearing potential (CBP) must agree to use two medically acceptable methods of contraception throughout the study. Men with sexual partners of CBP must agree to use a condom please one additional method of contraception (used by their female partner) throughout the study.

• Participants must meet the following baseline organ function, indicated by laboratory criteria as Screening:

∙ Renal: Estimated glomerular filtration rate (eGFR) of ≥45 ml/min/1.73m\^2.

‣ Hepatic: Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and total bilirubin ≤1.5 upper limit of normal (ULN) range at Screening. For participants with a history of Gilbert's Syndrome, total bilirubin ≤2 × ULN.

‣ Hematology (Hgb): Hemoglobin \>85 g/L and platelet count \>120 x 10\^9/L.

⁃ PART B ONLY- Participants must be symptomatic (typically reporting bleeding events every month) with a minimum of 3 treated bleeding events reported in either the observational study HMB-002-101\_SCR or in the participant's medical record.

⁃ Part B only: Participants may be enrolled if they have completed Part A follow-up.